

ASX / Media Release

1 April 2010

RHT: Fibrosis Test Update

Resonance Health is pleased to announce that it has finished patient recruitment and MRI scanning for the current phase of development of an MRI test for the measurement of liver fibrosis.

The Company is currently analysing the data and will provide an update to shareholders at the conclusion of this process, which is expected to be by the end of April, 2010.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@ferriscan.com

Eva O'Malley
Company Secretary
T: +61 8 9286 5300
E: evao@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing core laboratory services utilising advanced medical technology for the analysis of medical images. Its patented technology FerriScan[®] provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. Initial commercialisation of FerriScan[®] has focused on pharmaceutical companies developing drug therapies to treat iron overload, and is now being extended to the broader international clinical community.